CR20130649A - Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos - Google Patents
Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicosInfo
- Publication number
- CR20130649A CR20130649A CR20130649A CR20130649A CR20130649A CR 20130649 A CR20130649 A CR 20130649A CR 20130649 A CR20130649 A CR 20130649A CR 20130649 A CR20130649 A CR 20130649A CR 20130649 A CR20130649 A CR 20130649A
- Authority
- CR
- Costa Rica
- Prior art keywords
- methyl
- organic acids
- banzamide
- metil
- penyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se inventaron composiciones farmacéuticas solubles denilotinib, o de una sal farmacéuticamente aceptable del mismo,utilizando uno o más ácidos orgánicos que funcionan como un agente solubilizante, que aumentan la biodisponibilidad del nilotinib, y que suprimen el efecto del alimento asociado con ciertas composiciones de nilotinib.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161496913P | 2011-06-14 | 2011-06-14 | |
US201161541306P | 2011-09-30 | 2011-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20130649A true CR20130649A (es) | 2014-02-04 |
Family
ID=46317545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20130649A CR20130649A (es) | 2011-06-14 | 2013-12-12 | Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos |
Country Status (20)
Country | Link |
---|---|
US (1) | US20150273070A1 (es) |
EP (1) | EP2721024A1 (es) |
JP (1) | JP2014517040A (es) |
KR (1) | KR20140036225A (es) |
CN (1) | CN103608342A (es) |
AP (1) | AP2013007233A0 (es) |
AR (1) | AR086913A1 (es) |
BR (1) | BR112013032122A2 (es) |
CA (1) | CA2838741A1 (es) |
CL (1) | CL2013003576A1 (es) |
CO (1) | CO6801777A2 (es) |
CR (1) | CR20130649A (es) |
EA (1) | EA201490014A1 (es) |
GT (1) | GT201300309A (es) |
IL (1) | IL229395A0 (es) |
MX (1) | MX2013014788A (es) |
PE (1) | PE20141318A1 (es) |
SG (1) | SG194756A1 (es) |
TW (1) | TW201311246A (es) |
WO (1) | WO2012174082A1 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3251673A1 (en) | 2012-12-13 | 2017-12-06 | IP Gesellschaft für Management mbH | Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer |
KR101633292B1 (ko) * | 2014-02-25 | 2016-06-24 | 동아에스티 주식회사 | 용법이 개선된 엔테카비어를 함유하는 약학적 조성물 |
WO2015130083A1 (ko) * | 2014-02-25 | 2015-09-03 | 동아에스티 주식회사 | 용법이 개선된 엔테카비어를 함유하는 약학적 조성물 |
US10016423B2 (en) | 2014-10-16 | 2018-07-10 | Apotex Inc. | Solid forms of nilotinib hydrochloride |
WO2017158625A1 (en) | 2016-03-17 | 2017-09-21 | Sun Pharmaceutical Industries Ltd. | Pharmaceutical composition of nilotinib |
SG11201808582RA (en) | 2016-03-28 | 2018-10-30 | Incyte Corp | Pyrrolotriazine compounds as tam inhibitors |
US10449195B2 (en) | 2016-03-29 | 2019-10-22 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical formulation of palbociclib and a preparation method thereof |
IL271759B2 (en) * | 2017-07-19 | 2024-01-01 | Ignyta Inc | Pharmaceutical preparations that include anthraxtinib |
CZ2017821A3 (cs) | 2017-12-20 | 2019-07-03 | Zentiva, K.S. | Léková forma obsahující krystalický nilotinib |
TWI770624B (zh) * | 2018-06-15 | 2022-07-11 | 漢達生技醫藥股份有限公司 | 尼洛替尼十二烷基硫酸鹽在製備用於治療慢性骨髓性白血病之劑型的用途 |
US11241438B2 (en) | 2018-06-29 | 2022-02-08 | Incyte Corporation | Formulations of an AXL/MER inhibitor |
WO2020101597A2 (en) * | 2018-08-27 | 2020-05-22 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Capsule compositions comprising tyrosine-kinase inhibitors |
JP7211644B2 (ja) * | 2019-02-18 | 2023-01-24 | スレイバック・ファーマ・エルエルシー | ニロチニブの医薬組成物 |
JP7378279B2 (ja) * | 2019-11-18 | 2023-11-13 | 日本化薬株式会社 | ニロチニブを有効成分とする医薬錠剤及びその製造方法 |
IL295007A (en) | 2020-01-31 | 2022-09-01 | Nanocopoeia Llc | Amorphous nilotinib microparticles and uses thereof |
EP4142699A1 (en) | 2020-04-30 | 2023-03-08 | Nanocopoeia LLC | Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib |
JP7489849B2 (ja) | 2020-07-20 | 2024-05-24 | 日本化薬株式会社 | ニロチニブ錠剤 |
JP2023534737A (ja) * | 2020-07-24 | 2023-08-10 | ロンザ・ベンド・インコーポレーテッド | 酢酸を含むapiの過飽和溶液の噴霧乾燥 |
WO2022068876A1 (en) * | 2020-09-29 | 2022-04-07 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical compositions |
CN114306245A (zh) | 2020-09-29 | 2022-04-12 | 深圳市药欣生物科技有限公司 | 无定形固体分散体的药物组合物及其制备方法 |
EP4355306A1 (en) | 2021-06-19 | 2024-04-24 | Helm AG | Granulate composition comprising nilotinib |
EP4122452A1 (en) * | 2021-07-23 | 2023-01-25 | KRKA, d.d., Novo mesto | Pharmaceutical composition comprising nilotinib and method of manufacturing the same |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE424815T1 (de) * | 2001-12-03 | 2009-03-15 | Dor Biopharma Inc | Stabilisierte umkehr-mizellen-zusammensetzungen und ihre verwendung |
CN101184748B (zh) * | 2005-06-09 | 2011-09-28 | 诺瓦提斯公司 | 合成5-(甲基-1h-咪唑-1-基)-3-(三氟甲基)苯胺的方法 |
SA06270147B1 (ar) * | 2005-06-09 | 2009-12-22 | نوفارتيس ايه جي | عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين |
GT200600316A (es) * | 2005-07-20 | 2007-04-02 | Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida. | |
CN101228150B (zh) * | 2005-07-20 | 2014-10-15 | 诺华股份有限公司 | 4-甲基-n-[3-(4-甲基-咪唑-1-基)-5-三氟甲基-苯基]-3-(4-吡啶-3-基-嘧啶-2-基氨基)-苯甲酰胺的晶形 |
CN101228151B (zh) * | 2005-07-20 | 2013-01-09 | 诺瓦提斯公司 | 4-甲基-n-[3-(4-甲基-咪唑-1-基)-5-三氟甲基-苯基]-3-(4-吡啶-3-基-嘧啶-2-基氨基)-苯甲酰胺的盐 |
GT200600315A (es) | 2005-07-20 | 2007-03-19 | Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida | |
CN101505736A (zh) * | 2006-08-25 | 2009-08-12 | 贝林格尔.英格海姆国际有限公司 | 控制释放系统及其制造方法 |
EP1923053A1 (en) * | 2006-09-27 | 2008-05-21 | Novartis AG | Pharmaceutical compositions comprising nilotinib or its salt |
EP2089003A1 (en) * | 2006-11-09 | 2009-08-19 | Abbott GmbH & Co. KG | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
GB0716591D0 (en) * | 2007-08-24 | 2007-10-03 | Vereniging Het Nl Kanker I | Composition |
EP2305667A3 (en) * | 2008-07-17 | 2011-05-11 | Teva Pharmaceutical Industries Ltd. | Nilotinib intermediates and preparation thereof |
TW201022240A (en) * | 2008-11-05 | 2010-06-16 | Teva Pharma | Nilotinib HCl crystalline forms |
ES2555263T3 (es) * | 2010-06-21 | 2015-12-30 | Teva Pharmaceutical Industries Ltd. | Sales de Nilotinib y formas cristalinas de las mismas |
-
2012
- 2012-06-12 AR ARP120102086A patent/AR086913A1/es unknown
- 2012-06-13 KR KR1020137032874A patent/KR20140036225A/ko not_active Application Discontinuation
- 2012-06-13 CA CA2838741A patent/CA2838741A1/en not_active Abandoned
- 2012-06-13 EA EA201490014A patent/EA201490014A1/ru unknown
- 2012-06-13 AP AP2013007233A patent/AP2013007233A0/xx unknown
- 2012-06-13 SG SG2013081344A patent/SG194756A1/en unknown
- 2012-06-13 BR BR112013032122A patent/BR112013032122A2/pt not_active IP Right Cessation
- 2012-06-13 TW TW101121210A patent/TW201311246A/zh unknown
- 2012-06-13 MX MX2013014788A patent/MX2013014788A/es not_active Application Discontinuation
- 2012-06-13 PE PE2013002815A patent/PE20141318A1/es not_active Application Discontinuation
- 2012-06-13 JP JP2014515941A patent/JP2014517040A/ja active Pending
- 2012-06-13 US US14/126,219 patent/US20150273070A1/en not_active Abandoned
- 2012-06-13 EP EP12728015.4A patent/EP2721024A1/en not_active Withdrawn
- 2012-06-13 WO PCT/US2012/042205 patent/WO2012174082A1/en active Application Filing
- 2012-06-13 CN CN201280029595.2A patent/CN103608342A/zh active Pending
-
2013
- 2013-11-11 IL IL229395A patent/IL229395A0/en unknown
- 2013-11-14 CO CO13268350A patent/CO6801777A2/es not_active Application Discontinuation
- 2013-12-12 GT GT201300309A patent/GT201300309A/es unknown
- 2013-12-12 CR CR20130649A patent/CR20130649A/es unknown
- 2013-12-13 CL CL2013003576A patent/CL2013003576A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
BR112013032122A2 (pt) | 2016-12-13 |
PE20141318A1 (es) | 2014-10-13 |
AP2013007233A0 (en) | 2013-11-30 |
CN103608342A (zh) | 2014-02-26 |
MX2013014788A (es) | 2014-07-28 |
JP2014517040A (ja) | 2014-07-17 |
WO2012174082A1 (en) | 2012-12-20 |
CA2838741A1 (en) | 2012-12-20 |
US20150273070A1 (en) | 2015-10-01 |
AR086913A1 (es) | 2014-01-29 |
CO6801777A2 (es) | 2013-11-29 |
TW201311246A (zh) | 2013-03-16 |
SG194756A1 (en) | 2013-12-30 |
EA201490014A1 (ru) | 2014-04-30 |
KR20140036225A (ko) | 2014-03-25 |
GT201300309A (es) | 2015-02-19 |
IL229395A0 (en) | 2014-01-30 |
CL2013003576A1 (es) | 2014-07-11 |
EP2721024A1 (en) | 2014-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20130649A (es) | Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos | |
PH12018500284A1 (en) | 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer | |
MY191574A (en) | Pharmaceutical compositions comprising meloxicam | |
EA201201263A1 (ru) | Фармацевтическая композиция, содержащая этексилат дабигатрана | |
PE20190405A1 (es) | FORMULACION PARA ANTICUERPO ANTI-alfa4beta7 | |
PE20141822A1 (es) | Inhibidor de la quinasa reguladora de la senal de apoptosis | |
NZ721298A (en) | Pharmaceutical compositions comprising azd9291 | |
TN2018000452A1 (en) | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof | |
CL2012000092A1 (es) | Compuestos derivados de piridina y pirazina o una sal de los mismos, moduladores de proteina quinasa cdk9; composicion farmaceutica que los comprende, util para el tratamiento del cancer, hipotrofia cardiaca, vih y enfermedades inflamatorias. | |
BR112016008576A2 (pt) | Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária | |
CL2016001918A1 (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
CO2017006898A2 (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
IT1404931B1 (it) | Composizioni oftalmiche per la somministrazione di principi attivi liposolubili . | |
CO2017005544A2 (es) | Tableta multicapa que contiene fármaco inestable a la luz | |
IN2014MU01042A (es) | ||
EP3162802A4 (en) | 2-(3-pyridinyl)-1h-benzimidazole derivative compound and medicine containing same | |
DK3103453T3 (da) | Medicinsk sammensætning omfattende heterocyklisk diamino-carboxamidforbindelse som aktiv bestanddel | |
MX2015014958A (es) | Nuevos derivados de triazolona o sales de la misma y composicion farmaceutica que comprende a la misma. | |
MX2021003230A (es) | Composiciones farmaceuticas que comprenden meloxicam. | |
GT201400094A (es) | Formulación de liberación inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)-fenil]-benzamida | |
CL2017001478A1 (es) | Combinación de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anti-cáncer con un inhibidor de factor de crecimiento epidérmico (egfr) | |
EP3733661A4 (en) | COMPOS &XC9; DE D &XC9; RIV &XC9; 2 - [5 -IMIDAZOLE - &XFF11; -YLM &XC9; THYL) PYRIDINE- &XFF13; -YL] BENZIMIDAZOLE, AND M &XC9; DICAMENT CONTAINING THIS ONE | |
MX2017004359A (es) | Composiciones farmaceuticas que comprenden alpelisib. | |
EP3019182A4 (en) | COMPOSITION COMPRISING A PURIFIED EXTRACT ISOLATED FROM PSEUDOLYSIMACHION ROTUNDUM VAR. SUBINTEGRUM CONTAINING AN ABUNDANT QUANTITY OF ACTIVE PRINCIPLE OR COMPOUNDS ISOLATED THEREOF AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF OBSTRUCTIVE CHRONIC BRONCHOPNEUMOPATHY AND USE THEREOF | |
EA201500368A1 (ru) | Фармацевтическая композиция 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей для лечения кардиоваскулярной патологии |